Scholarlink

<p>Precision medicine has expanded therapeutic options for rare central nervous system tumors, yet actionable molecular targets remain limited in pediatric cases. Functional ex vivo drug-response assays may complement genomic approaches by identifying tumor-specific sensitivities. Clival chordoma is a rare, locally aggressive tumor generally considered chemotherapy-refractory, particularly in children. We report the prospective use of a functional drug-response platform (Bioverso Test) to guide treatment in a pediatric patient with recurrent metastatic clival chordoma. A four-year-old patient with intracranial and pulmonary disease underwent testing using three-dimensional tumor microspheroids. The assay demonstrated broad resistance, with relative sensitivity to irinotecan (CPT-11). Treatment with an irinotecan-based regimen (50&#xa0;mg/m²/day, days 1–5) resulted in a marked clinical and radiological response after three cycles, with significant reduction of intracranial and pulmonary lesions and no severe toxicities. The response has been sustained for 14 months. This case illustrates the clinical utility of integrating functional drug-response data into real-time decision-making, supporting a role for functional precision oncology in rare and treatment-refractory pediatric tumors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prediction of personalized therapeutic response in pediatric clivus chordoma: chemoresistance test

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月26日

查看全文
  • Sérgio Cavalheiro,
  • Lorena Favaro Pavon,
  • Caroline Brunetto de Farias,
  • Flávia Borelli Nascimento,
  • Martina Lichtenfels,
  • Jessica Benigno Rodrigues,
  • Natalia Dassi,
  • Andreia Cappellano,
  • Patrícia Alesssandra Dastoli,
  • Thais Cristina de Souza Melo,
  • Fernando Suzuki,
  • Rodrigo Akira Watanabe,
  • Isaque Hyung Tong Kim,
  • Francine Tesser-Gamba,
  • Thais Biude Mendes,
  • Franz Onish,
  • Marcos Devanir Silva da Costa

摘要

Precision medicine has expanded therapeutic options for rare central nervous system tumors, yet actionable molecular targets remain limited in pediatric cases. Functional ex vivo drug-response assays may complement genomic approaches by identifying tumor-specific sensitivities. Clival chordoma is a rare, locally aggressive tumor generally considered chemotherapy-refractory, particularly in children. We report the prospective use of a functional drug-response platform (Bioverso Test) to guide treatment in a pediatric patient with recurrent metastatic clival chordoma. A four-year-old patient with intracranial and pulmonary disease underwent testing using three-dimensional tumor microspheroids. The assay demonstrated broad resistance, with relative sensitivity to irinotecan (CPT-11). Treatment with an irinotecan-based regimen (50 mg/m²/day, days 1–5) resulted in a marked clinical and radiological response after three cycles, with significant reduction of intracranial and pulmonary lesions and no severe toxicities. The response has been sustained for 14 months. This case illustrates the clinical utility of integrating functional drug-response data into real-time decision-making, supporting a role for functional precision oncology in rare and treatment-refractory pediatric tumors.